Browse
Topics & Collections
Search for a specific
disease or term
—  or  —
Learn more about ACP Smart Medicine

Dynamed

X
This content was provided by DynaMed (dynamed.ebscohost.com). For more information click here.
Last Updated: 4/21/2014  

Diabetes in Pregnancy

  • Counsel all diabetic women of childbearing potential on the need for pregnancy planning.

  • Optimize glycemic control and stop teratogenic medications (including ACE inhibitors and angiotensin-receptor blockers) before conception.

  • Screen all pregnant nondiabetic women for gestational diabetes at 24 to 28 weeks gestation using a 75g 2-hour OGTT.

  • Use laboratory testing to evaluate diabetic control (using HbA1C) in diabetic women who become pregnant and follow HbA1C every 2 to 3 months during pregnancy.

  • Use metformin, glyburide, or insulin in pregnant patients with diabetes to achieve optimal glycemic control, with the goal of fasting glucose levels of ≤95 mg/dL and 2-hour postprandial glucose levels of ≤140 mg/dL.

DOI: 10.7326/d942
The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP.
Disclosures:
Elisha L. Brownfield, MD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Justin B. Moore, MD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Deborah Korenstein, MD, FACP, Editor in Chief, ACP Smart Medicine, has no relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Richard B. Lynn, MD, FACP, Editor, ACP Smart Medicine, has no relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.
Related Content
Annals of Internal Medicine